Literature DB >> 11122857

New developments in melanoma genetics.

N Hayward1.   

Abstract

Research over the last decade has unraveled many details of genetic susceptibility to melanoma. The most recent advances include the characterization of variants outside the coding region of the CDKN2A gene associated with melanoma predisposition. A mutation in the 5' untranslated region (UTR) of CDKN2A generates a novel upstream initiation codon that abrogates expression of p16, and a common polymorphism in the 3' UTR is associated with increasing familial risk of melanoma. Other studies have assessed CDKN2A mutation status and non-melanoma cancers, atypical nevi, and the development of multiple primary melanomas, and provided information valuable for screening of individuals who are at risk.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11122857     DOI: 10.1007/s11912-000-0022-z

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  40 in total

1.  CDKN2A variants in a population-based sample of Queensland families with melanoma.

Authors:  J Aitken; J Welch; D Duffy; A Milligan; A Green; N Martin; N Hayward
Journal:  J Natl Cancer Inst       Date:  1999-03-03       Impact factor: 13.506

2.  The atypical-mole syndrome and predisposition to melanoma.

Authors:  R C Wachsmuth; M Harland; J A Bishop
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

3.  Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma.

Authors:  L Liu; D Dilworth; L Gao; J Monzon; A Summers; N Lassam; D Hogg
Journal:  Nat Genet       Date:  1999-01       Impact factor: 38.330

4.  Affected members of melanoma-prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARF.

Authors:  L Liu; A M Goldstein; M A Tucker; H Brill; N A Gruis; D Hogg; N J Lassam
Journal:  Genes Chromosomes Cancer       Date:  1997-05       Impact factor: 5.006

5.  Familial melanoma and pancreatic cancer. Ligurian Skin Tumor Study Group.

Authors:  P Ciotti; P Strigini; G Bianchi-Scarrà
Journal:  N Engl J Med       Date:  1996-02-15       Impact factor: 91.245

6.  Genetic and environmental influences in the development of multiple primary melanoma.

Authors:  A D Burden; J Newell; N Andrew; G Kavanagh; J M Connor; R M MacKie
Journal:  Arch Dermatol       Date:  1999-03

7.  Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population.

Authors:  M G FitzGerald; D P Harkin; S Silva-Arrieta; D J MacDonald; L C Lucchina; H Unsal; E O'Neill; J Koh; D M Finkelstein; K J Isselbacher; A J Sober; D A Haber
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

8.  Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds.

Authors:  J F Flores; P M Pollock; G J Walker; J M Glendening; A H Lin; J M Palmer; M K Walters; N K Hayward; J W Fountain
Journal:  Oncogene       Date:  1997-12-11       Impact factor: 9.867

9.  Functional evidence of novel tumor suppressor genes for cutaneous malignant melanoma.

Authors:  C N Parris; J D Harris; D K Griffin; A P Cuthbert; A J Silver; R F Newbold
Journal:  Cancer Res       Date:  1999-02-01       Impact factor: 12.701

10.  Increasing incidence of cutaneous melanoma in Queensland, Australia.

Authors:  R MacLennan; A C Green; G R McLeod; N G Martin
Journal:  J Natl Cancer Inst       Date:  1992-09-16       Impact factor: 13.506

View more
  12 in total

1.  Analysis of the miR-34a locus in 62 patients with familial cutaneous melanoma negative for CDKN2A/CDK4 screening.

Authors:  Angela M Cozzolino; Lucia Pedace; Marco Castori; Paola De Simone; Nicoletta Preziosi; Isabella Sperduti; Chiara Panetta; Valerio Mogini; Carmelilia De Bernardo; Aldo Morrone; Caterina Catricalà; Paola Grammatico
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

2.  Cooperativity of Cdk4R24C and Ras in melanoma development.

Authors:  Rachna Chawla; Judith A Procknow; Ramana V Tantravahi; Jasvir S Khurana; Judith Litvin; E Premkumar Reddy
Journal:  Cell Cycle       Date:  2010-08-10       Impact factor: 4.534

Review 3.  Familial melanoma: a complex disorder leading to controversy on DNA testing.

Authors:  Femke A de Snoo; Wilma Bergman; Nelleke A Gruis
Journal:  Fam Cancer       Date:  2003       Impact factor: 2.375

Review 4.  [The dysplastic nevus. Separate entity, melanoma precursor or diagnostic dilemma?].

Authors:  A Roesch; M Landthaler; T Vogt
Journal:  Hautarzt       Date:  2003-09       Impact factor: 0.751

5.  New microRNAs from mouse and human.

Authors:  Mariana Lagos-Quintana; Reinhard Rauhut; Jutta Meyer; Arndt Borkhardt; Thomas Tuschl
Journal:  RNA       Date:  2003-02       Impact factor: 4.942

Review 6.  Melanomagenesis: overcoming the barrier of melanocyte senescence.

Authors:  Linan Ha; Glenn Merlino; Elena V Sviderskaya
Journal:  Cell Cycle       Date:  2008-04-23       Impact factor: 4.534

Review 7.  NF-kappaB activation in melanoma.

Authors:  Yukiko Ueda; Ann Richmond
Journal:  Pigment Cell Res       Date:  2006-04

8.  MC1R is a potent regulator of PTEN after UV exposure in melanocytes.

Authors:  Juxiang Cao; Lixin Wan; Elke Hacker; Xiangpeng Dai; Stefania Lenna; Celia Jimenez-Cervantes; Yongjun Wang; Nick R Leslie; George X Xu; Hans R Widlund; Byungwoo Ryu; Rhoda M Alani; Ken Dutton-Regester; Colin R Goding; Nicholas K Hayward; Wenyi Wei; Rutao Cui
Journal:  Mol Cell       Date:  2013-08-22       Impact factor: 17.970

9.  Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma.

Authors:  N Soufir; J J Lacapere; G Bertrand; E Matichard; R Meziani; D Mirebeau; V Descamps; B Gérard; A Archimbaud; L Ollivaud; F Bouscarat; M Baccard; G Lanternier; P Saïag; C Lebbé; N Basset-Seguin; B Crickx; H Cave; B Grandchamp
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

10.  Involvement of ANXA5 and ILKAP in susceptibility to malignant melanoma.

Authors:  Yoana Arroyo-Berdugo; Santos Alonso; Gloría Ribas; Maider Ibarrola-Villava; María Peña-Chilet; Conrado Martínez-Cadenas; Jesús Gardeazabal; Juan Antonio Ratón-Nieto; Ana Sánchez-Díez; Jesús María Careaga; Gorka Pérez-Yarza; Gregorio Carretero; Manuel Martín-González; Cristina Gómez-Fernández; Eduardo Nagore; Aintzane Asumendi; María Dolores Boyano
Journal:  PLoS One       Date:  2014-04-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.